CINECA IRIS Institutional Research Information System

FONTANINI, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.802
EU - Europa 7.313
AS - Asia 3.205
AF - Africa 320
SA - Sud America 25
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 9
Totale 29.689
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.307
IT - Italia 2.052
CN - Cina 1.544
DE - Germania 1.303
SE - Svezia 1.198
BG - Bulgaria 896
SG - Singapore 671
GB - Regno Unito 494
CA - Canada 490
UA - Ucraina 439
VN - Vietnam 367
TR - Turchia 348
FI - Finlandia 308
CI - Costa d'Avorio 188
CH - Svizzera 132
RU - Federazione Russa 128
HK - Hong Kong 116
AT - Austria 110
FR - Francia 100
IN - India 96
SN - Senegal 76
BE - Belgio 52
NG - Nigeria 39
BR - Brasile 21
NL - Olanda 19
PL - Polonia 16
AU - Australia 14
ID - Indonesia 13
BJ - Benin 10
ES - Italia 10
RO - Romania 10
CZ - Repubblica Ceca 9
DK - Danimarca 9
EU - Europa 9
IL - Israele 9
JP - Giappone 9
KR - Corea 8
IE - Irlanda 5
HU - Ungheria 4
IR - Iran 4
AL - Albania 3
LU - Lussemburgo 3
MD - Moldavia 3
MX - Messico 3
TH - Thailandia 3
EE - Estonia 2
EG - Egitto 2
GE - Georgia 2
GR - Grecia 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MY - Malesia 2
PK - Pakistan 2
PT - Portogallo 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
IQ - Iraq 1
LK - Sri Lanka 1
LY - Libia 1
MT - Malta 1
NZ - Nuova Zelanda 1
PA - Panama 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 29.689
Salva come PNG Salva come JPEG
Città #
Fairfield 2.258
Woodbridge 2.132
Chandler 1.732
Houston 1.588
Ann Arbor 1.415
Ashburn 1.127
Seattle 951
Sofia 896
Wilmington 849
Cambridge 798
Beijing 586
New York 529
Jacksonville 471
Ottawa 460
Boardman 426
Milan 391
Princeton 390
Lawrence 363
Izmir 326
Medford 324
Singapore 321
Nanjing 292
Des Moines 258
Serra 245
Pisa 210
Abidjan 188
Florence 174
Dong Ket 163
Dearborn 155
Boulder 133
Bern 124
San Diego 114
Vienna 107
Hong Kong 106
Nanchang 98
Falls Church 89
Bremen 82
Kunming 79
Ogden 78
Frankfurt am Main 77
Dakar 76
Jüchen 70
Lancaster 67
London 63
Hebei 50
Shenyang 50
Brussels 49
Pune 47
Redwood City 47
Lagos 39
Los Angeles 38
Hefei 37
Jiaxing 37
Changsha 36
Rome 33
Shanghai 32
Seacroft 30
Chicago 29
Düsseldorf 29
Fuzhou 27
Tianjin 27
Washington 26
Norwalk 24
Nürnberg 24
Auburn Hills 22
Dallas 22
Guangzhou 20
Hangzhou 19
Orange 19
Phoenix 19
Jinan 18
Quanzhou 17
Verona 17
Kent 15
Vicopisano 15
San Francisco 14
Rho 13
Warsaw 13
Toronto 12
Bologna 11
Changchun 11
Santa Clara 11
Cotonou 10
Indiana 10
Marseille 10
Lucca 9
Sezze 9
Council Bluffs 8
Edinburgh 8
Genoa 8
Lanzhou 8
Redmond 8
Turin 8
Alessandria 7
Istanbul 7
Baotou 6
Capannori 6
Lappeenranta 6
Las Vegas 6
Lugo 6
Totale 22.520
Salva come PNG Salva come JPEG
Nome #
null 346
La densità microvascolare (DMV) come marker prognostico e predittivo nelle neoplasie maligne dell'albero bronchiale in fase avanzata. 220
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 186
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 178
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 164
An atypical presentation of sporadic adult-onset centronuclear myopathy 159
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 156
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 152
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 151
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts 149
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 147
Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience 144
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 143
Second primary lung cancer and relapse: treatment and follow-up. 142
Reply to P.M. Foye ( Letter ) 142
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 141
Percutaneous radiofrequency ablation (pRTA) of pulmonary tumors 138
null 138
Evaluation of telomerase in the development and progression of colon cancer. Int J Mol Med. 2002 Nov;10(5):589-92 136
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments 134
Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report 133
Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction 132
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma 130
null 130
null 129
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center 129
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 128
TERMOABLAZIONE DI NEOPLASIE POLMONARI MALIGNE: QUALI PROSPETTIVE 128
Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas 126
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 125
Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma. 125
Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features 123
Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma 122
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 121
Alterations of Fas (APO-1/CD95) gene and its relationship with p53 in non small cell lung cancer 121
210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia 121
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 120
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 120
null 116
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. 116
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 115
ANTIGENIC EXPRESSION OF M2 PYRUVATE-KINASE IN COLON RECTAL CANCER.PRELIMINARY RESULTS OF AN IMMUNOISTCHEMICAL STUDY 114
KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung 114
Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology? 114
A high vascular count and overexpression of Vascular Endothelial Growth Factor (VEGF) are associated with unfavorable prognosis in operated Small Cell Carcinoma (SCLC) 112
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients 112
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 112
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 112
null 111
Accumulation of gene protein product P53 correlates with high microvessel count in non small cell lung carcinomas 111
null 111
FR-MLV INFECTION INDUCES ERYTHROLEUKEMIA INSTEAD OF LYMPHOID LEUKEMIA IN MICE GIVEN PITUITARY GRAFTS 110
Neoangiogenesis as prognostic indicator of survival in lung cancer. 109
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 108
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 107
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance 107
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 107
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 107
A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. 107
miR-19a and miR-20a and tissue factor expression in activated human peripheral blood mononuclear cells 106
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: A literature review 106
Nodal upstaging evaluation in NSCLC patients treated by robotic lobectomy 106
2ND PRIMARY LUNG-CANCER AND RELAPSE - TREATMENT AND FOLLOW-UP 105
MicroRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers 105
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 105
Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study 104
Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer 104
Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival? 104
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 104
Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer 103
CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma 103
Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma 103
null 103
Screen-detected multiple primary lung cancers in the ITALUNG trial 103
WWOX expression in different histologic types and subtypes of non-small cell lung cancer 102
THE EXPRESSION OF PROLIFERATING CELL NUCLEAR ANTIGEN IN PARAFFIN SECTIONS OF PERIPHERAL, NODE-NEGATIVE NON-SMALL-CELL LUNG-CANCER 101
A preliminary study on radiofrequency thermal ablation of lung tumors 101
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). 101
ANGIOGENIC POTENTIAL IN-VIVO BY KAPOSIS-SARCOMA CELL-FREE SUPERNATANTS AND HIV-1 TAT PRODUCT - INHIBITION OF KS-LIKE LESIONS BY TISSUE INHIBITOR OF METALLOPROTEINASE-2 100
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 100
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 100
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial 100
Novel MTCYB mutation in a young patient with recurrent stroke-like episodes and status epilepticus 100
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 99
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. 99
null 98
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 97
Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. 97
Markers of cell proliferation as prognostic factors in differentiated thyroid cancer. 96
BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. 96
Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. 96
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A 95
VALUTAZIONE DELL'ATTIVITA' TELOMERASICA E DELL'ESPRESSIONE DI hTERT mRNA IN ADENOCARCINOMA DEL COLON 95
The multimodality treatment of thymic carcinoma 95
Evaluation of telomerase in non-melanoma skin cancer 95
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma 95
COINVOLGIMENTO DEL SISTEMA FAS(CD95/APO-1)/FAS LIGANDO NEL PROCESSO DI APOPTOSI p53-MEDIATO IN ADENOCARCINOMI DEL COLON 94
Clear cell adenocarcinoma of the base of the tongue: a case report and review of the literature 94
EXPRESSION OF P21 RAS PROTEIN AS A PROGNOSTIC FACTOR IN PAPILLARY THYROID-CANCER 94
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 94
Totale 11.959
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.220
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.220
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.569 0 0 0 419 662 652 723 484 593 451 478 107
2020/20212.840 271 158 217 112 372 146 176 271 271 215 164 467
2021/20224.001 48 289 112 219 757 636 105 193 200 168 155 1.119
2022/20234.685 551 537 294 478 558 653 25 376 840 19 324 30
2023/20242.972 315 316 392 140 432 585 84 84 80 45 150 349
2024/2025836 82 447 86 221 0 0 0 0 0 0 0 0
Totale 30.270